Like Generex Corp., Titan Pharmaceuticals has a conference call scheduled for this week.
Titan's call will be held on Tuesday the 29th of March at 1PM EST and the subject will be the fourth quarter and full year 2010 results, which were released late last week.
No surprises resulted from the quarterly and full-year filing, and it looks like the Probuphine Phase III confirmatory results are set to be released by the end of the second quarter.
A pre-NDA meeting with the FDA is scheduled for August.
It's been quite a while of going-it-alone for Titan since the approval of Vanda's Fanapt and the development of Probuphine, but I'm still of the belief that this company is going to be on the receiving end of a buyout before long.
If not a buyout, it could be a partnership is going to develop once the Probuphine results are known.
TTNP has held up nicely, although with some volatility, since the announcement of the Deerfield credit facility, indicating a neutral reaction from the market.
Having traded for just a penny only a couple of years ago, Titan is already a huge success story for the recent past, but there could be more to come as Probuphine and the ProNeura pipeline develops.
Eyes on Tuesday for Titan investors.
Disclosure: Long TTNP.